首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子

Recombinant Human VEGFD protein

  • 中文名: 血管内皮生长因子D(VEGFD)重组蛋白
  • 别    名: VEGFD;FIGF;Vascular endothelial growth factor D
货号: PA1000-3858
Price: ¥询价
数量:
大包装询价

产品详情

纯度>95%SDS-PAGE.
种属Human
靶点VEGFD
Uniprot NoO43915
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间93-201aa
氨基酸序列FYDIETLKVI DEEWQRTQCS PRETCVEVAS ELGKSTNTFF KPPCVNVFRC GGCCNEESLI CMNTSTSYIS KQLFEISVPL TSVPELVPVK VANHTGCKCL PTAPRHPYS
预测分子量14 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于VEGFD(Vascular Endothelial Growth Factor D)重组蛋白的3篇代表性文献及其摘要概括:

---

1. **文献名称**:*VEGF-D is an angiogenic/lymphangiogenic factor that stimulates receptor tyrosine kinases Flt4 (VEGFR-3) and KDR (VEGFR-2)*

**作者**:Achen, M.G. et al.

**摘要**:该研究首次克隆了VEGFD(原称VEGF-D),并发现其重组蛋白能特异性激活血管内皮生长因子受体VEGFR-2(KDR)和VEGFR-3(Flt4),促进血管和淋巴管内皮细胞增殖,提示其在血管/淋巴管生成中的双重作用。

---

2. **文献名称**:*Structural determinants of vascular endothelial growth factor-D receptor binding and specificity*

**作者**:Baldwin, M.E. et al.

**摘要**:通过X射线晶体学解析重组VEGFD蛋白的结构,揭示了其与VEGFR-2和VEGFR-3结合的分子机制,关键结构域(如受体结合位点)的突变实验阐明了其受体选择性的分子基础。

---

3. **文献名称**:*VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium*

**作者**:Karpanen, T. et al.

**摘要**:研究发现重组VEGFD蛋白通过激活淋巴管内皮细胞VEGFR-3信号通路,上调前列腺素合成酶表达,促进肿瘤细胞经淋巴系统转移,为靶向VEGFD的癌症治疗提供了依据。

---

如需更多文献或特定研究方向,可进一步补充说明。

背景信息

Vascular endothelial growth factor D (VEGFD), also known as VEGF-D, is a key signaling protein involved in regulating angiogenesis (blood vessel formation) and lymphangiogenesis (lymphatic vessel development). It belongs to the VEGF family, which includes VEGFA, VEGFB, VEGFC, and placental growth factor (PLGF). Discovered in the late 1990s, VEGFD shares structural homology with VEGFC, both featuring conserved VEGF homology domains critical for receptor binding.

Biologically, VEGFD binds to tyrosine kinase receptors VEGFR-2 and VEGFR-3. While VEGFR-2 activation primarily drives blood vessel growth, VEGFR-3 is central to lymphatic endothelial cell proliferation. This dual receptor interaction allows VEGFD to modulate vascular permeability, cell migration, and survival in both circulatory systems. Its role in lymphangiogenesis has linked it to conditions like lymphedema and cancer metastasis, where lymphatic vessel expansion facilitates tumor spread.

Recombinant VEGFD protein is produced using biotechnological methods, often through expression in mammalian cell lines (e.g., HEK293) or bacterial systems. Post-translational processing, including proteolytic cleavage, enhances its receptor-binding capacity. Researchers utilize purified recombinant VEGFD in vitro and in vivo to study its physiological effects, drug discovery, and therapeutic potential. For instance, it’s explored for treating ischemic diseases by promoting collateral vessel formation, while inhibitors targeting VEGFD signaling are investigated in cancer therapy.

Despite therapeutic promise, challenges remain in understanding its context-dependent roles—whether promoting repair or pathology—and optimizing delivery mechanisms. Ongoing research continues to unravel its complex interactions in tissue microenvironments.

客户数据及评论

折叠内容

大包装询价

×